BioRestorative Therapies

About BioRestorative Therapies

BioRestorative Therapies is focused on developing therapeutic products using advanced cell and tissue protocols, primarily involving adult stem cells. Their clinical programs target critical healthcare needs such as degenerative disc disease and metabolic disorders, while their BioCosmeceutical platform explores innovative applications in aesthetic medicine.

Products & Services

BRTX-100:A bone marrow-derived mesenchymal stem cell product currently in a Phase 2 clinical trial for patients with chronic lumbar disc disease (cLDD).

ThermoStem:A brown adipose-derived stem cell product under development.

BioCosmeceuticals:A commercial product line featuring secretome (novel exosome, growth factor/cytokine) biologics-based technology for cosmetic applications.

BRTX-100 (bone marrow derived mesenchymal stem cells for cLDD)

Brown adipose derived stem cells (ThermoStem)

Secretome (exosome/growth factor) biologics for cosmetic applications

Specialties

Stem Cell Science Degenerative Disc Disease Treatment Metabolic Disorder Therapies Aesthetic Medicine (BioCosmeceuticals) Stem cell therapies Clinical trials for lumbar disc disease Cosmeceutical biologics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2026-02-13 FD: 2026-02-13	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: $5.0 Million FAN: 5000000	D: 2026-02-11 FD: 2026-02-11	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1085000 MR: - FA: $1.085 million FAN: 1085000	D: 2025-10-06 FD: 2025-10-06	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 8100000 MR: - FA: approximately $8.1 million FAN: 8100000	D: 2024-02-06 FD: 2024-02-06	-
5	RT: Insider Purchase T: - FT: Insider Purchase	A: 2800 MR: - FA: 2,800 FAN: 2800	D: 2023-08-02 FD: 2023-08-02	2 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2100000 MR: - FA: 2.1 million FAN: 2100000	D: 2023-07-11 FD: 2023-07-11	1 investors

Public Offering Latest

2026-02-13

$5.0M

1 investor (Pro only)

Public Offering 2026-02-11

$5.0M

Registered Direct Offering 2025-10-06

$1.1M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lance Alstodt

Chairman & CEO

R

Robert Kristal

Chief Financial Officer

F

Francisco Silva

Vice President of R&D

N

Nickolay Kukekov

President and CEO at KalGene Pharmaceuticals, Inc.

D

Dave Rosa

President & CEO at NeuroOne Medical Technologies Corp. (NASDAQ: NMTC)

P

Patrick F. Williams

Chief Financial Officer at STAAR Surgical

View 9 more team members with Pro

Unlock Full Team Directory

Recent News